KMS Medisurgi

Why is KMS Medisurgi Ltd falling/rising?

As of 17-Jul, KMS Medisurgi Ltd's stock price is Rs. 132.80, marking a new 52-week and all-time high, with a year-to-date gain of 4.98%. The stock has consistently outperformed its sector and moving averages, despite some erratic trading.

As of 17-Jul, KMS Medisurgi Ltd's stock price is rising. The current price is Rs. 132.80, which represents no change from the previous day, but it has reached a new 52-week and all-time high today. The stock opened with a gain of 4.98%, and it has consistently traded at this price throughout the day. Additionally, it has outperformed its sector by 8.7%. <BR><BR>The stock is also trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. Furthermore, the year-to-date performance shows a gain of 4.98%, contrasting sharply with the Sensex, which has declined by 8.30% during the same period. Over the past year, KMS Medisurgi Ltd has increased by 5.40%, while the Sensex has fallen by 4.99%. <BR><BR>Despite some erratic trading, where the stock did not trade on 5 out of the last 20 days, rising investor participation is evident, as indicated by a stable delivery volume. Overall, these factors contribute to the stock's rising performance.

Which are the latest news on KMS Medisurgi?

What does KMS Medisurgi do?

KMS Medisurgi Ltd is a micro-cap healthcare services company that manufactures and coats substrates with adhesive. It was incorporated in 1999 and became a public company in 2016, with a current market cap of INR 42 Cr.

Overview: <BR>KMS Medisurgi Ltd is a micro-cap company in the healthcare services industry that manufactures and undertakes job work of coating various substrates with adhesive.<BR><BR>History: <BR>KMS Medisurgi Limited was incorporated as "KMS Medisurgi Private Limited" on March 25, 1999, in Mumbai. The company converted into a Public Limited Company and changed its name to "KMS Medisurgi Limited" on June 15, 2016. Revenue and profit data are not available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 42 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 100.00 <BR>Industry P/E: 24 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.04 <BR>Return on Equity: 5.29% <BR>Price to Book: 5.02<BR><BR>Contact Details: <BR>Address: 297/301 May Building Grou. Flr, Marine (East) Princess Street Mumbai Maharashtra : 400002 <BR>Tel: 91-22-66107700/66107722 <BR>Email: kms.medisurgi@gmail.com <BR>Website: http://www.kmsgroup.in

How big is KMS Medisurgi?

Summary could not be generated.

As of 10th June, KMS Medisurgi Ltd has a market capitalization of 42.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent quarterly performance data is unavailable, so there are no figures for Net Sales or Net Profit for the latest four quarters.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds reported at 8.09 Cr and Total Assets at 10.22 Cr.

Who are in the management team of KMS Medisurgi?

The management team of KMS Medisurgi includes Rekha Devang Kanakia (Chairman & Managing Director), Kamlesh Chunilal Rajani, Hardik Rajnikant Bhatt, Pratik Pravin Tarpara (all Independent Directors), Siddharth Kanakia, Rohan Devang Kanakia (Directors), and Sunny Gupta (Company Secretary & Compliance Officer).

The management team of KMS Medisurgi includes the following individuals:<BR><BR>1. Rekha Devang Kanakia - Chairman & Managing Director<BR>2. Kamlesh Chunilal Rajani - Independent Director<BR>3. Hardik Rajnikant Bhatt - Independent Director<BR>4. Siddharth Kanakia - Director<BR>5. Pratik Pravin Tarpara - Independent Director<BR>6. Rohan Devang Kanakia - Director<BR>7. Sunny Gupta - Company Secretary & Compliance Officer<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

Who are the peers of the KMS Medisurgi?

KMS Medisurgi's peers include Royal Sense, Shree Pacetronix, Bandaram Pharma, and others. Management risk varies from excellent at Royal Sense to below average at Bandaram Pharma, with KMS Medisurgi showing average risk and a 1-year return of 6.24%.

Peers: The peers of KMS Medisurgi are Royal Sense, Shree Pacetronix, Bandaram Pharma, Amkay Products, N G Industries, Samsrita Labs, GKB Ophthalmics, Deccan Healthcar, and Centenial Surgic.<BR><BR>Quality Snapshot: Excellent management risk is observed at Royal Sense and N G Industries, while Good management risk is found at Shree Pacetronix, Amkay Products, and the rest. Average management risk is present at KMS Medisurgi, and Below Average management risk is noted at Bandaram Pharma, GKB Ophthalmics, Deccan Healthcar, and Centenial Surgic. Growth is Excellent at Royal Sense, Good at Shree Pacetronix, Bandaram Pharma, GKB Ophthalmics, and Deccan Healthcar, while KMS Medisurgi, Amkay Products, N G Industries, and Centenial Surgic exhibit Below Average growth. Samsrita Labs does not qualify for growth assessment.<BR><BR>Return Snapshot: Shree Pacetronix has the highest 1-year return at 66.27%, while Royal Sense has the lowest at -57.28%. KMS Medisurgi's 1-year return of 6.24% is better than Royal Sense's but lower than Shree Pacetronix's. Additionally, the six-month returns are negative for Royal Sense, Shree Pacetronix, Amkay Products, N G Industries, GKB Ophthalmics, Deccan Healthcar, and Centenial Surgic.

When is the next results date for KMS Medisurgi Ltd?

The next results date for KMS Medisurgi Ltd is 30 May 2026.

The next results date for KMS Medisurgi Ltd is scheduled for 30 May 2026.

Is KMS Medisurgi overvalued or undervalued?

As of September 16, 2025, KMS Medisurgi is considered very expensive and overvalued with a PE ratio of 41.75, an EV to EBIT ratio of 41.87, and a Price to Book Value of 5.45, underperforming the Sensex and raising concerns about its growth prospects.

As of 16 September 2025, the valuation grade for KMS Medisurgi has moved from risky to very expensive. The company is currently considered overvalued, with a PE ratio of 41.75, an EV to EBIT ratio of 41.87, and a Price to Book Value of 5.45. These figures suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, KMS Medisurgi's PE ratio is lower than Poly Medicure's 56.1 but higher than Blue Jet Health's 34.66, indicating a mixed competitive positioning. The PEG ratio stands at 0.00, which raises concerns about growth prospects relative to its valuation. Notably, while KMS Medisurgi has delivered a 1.2% return year-to-date, it has underperformed the Sensex, which has returned 5.43% in the same period, further reinforcing the notion of overvaluation.

Who are the top shareholders of the KMS Medisurgi?

The top shareholders of KMS Medisurgi are Moni Diamonds Limited with 19.21% and Yagnesh Manaharlal Joshi as the highest public shareholder at 5.82%. Individual investors hold a total of 21.7%, with no mutual fund or foreign institutional investor holdings and no pledged promoter shares.

The top shareholders of KMS Medisurgi include Moni Diamonds Limited, which holds the highest stake at 19.21%. Additionally, Yagnesh Manaharlal Joshi is the highest public shareholder with a holding of 5.82%. Overall, individual investors collectively hold 21.7% of the company's shares. The company does not have any mutual fund or foreign institutional investor (FII) holdings, and there are no pledged promoter holdings.

What is the technical trend for KMS Medisurgi?

As of April 15, 2024, KMS Medisurgi's technical trend is neutral, with the price stagnant at 125.00 and no significant movement in the 52-week high or low.

As of 15 April 2024, the technical trend for KMS Medisurgi has changed from mildly bullish to does not qualify. The current price is stagnant at 125.00, matching the previous close, with no movement in the 52-week high or low. Given the lack of significant price action and the absence of technical summary data, there is insufficient information to determine a clear bullish or bearish stance. The overall technical outlook is neutral.

How has been the historical performance of the KMS Medisurgi?

KMS Medisurgi has shown stable financial performance from March 2019 to March 2024, with increased total reserves and shareholder's funds, reduced long-term debt, and improved book value per share, despite reporting no profit before tax during the period. Total assets and liabilities remained consistent, indicating growth in equity while managing debt levels effectively.

Answer:<BR>The historical performance of KMS Medisurgi shows a consistent trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>KMS Medisurgi has maintained a stable share capital of Rs 3.30 crore from March 2019 to March 2024. Total reserves have increased from Rs 2.95 crore in March 2019 to Rs 4.36 crore in March 2024, indicating a positive trend in retained earnings. Shareholder's funds have also risen from Rs 6.25 crore in March 2019 to Rs 7.66 crore in March 2024. Long-term borrowings have decreased from Rs 1.13 crore in March 2019 to Rs 0.54 crore in March 2024, reflecting a reduction in debt levels. Total liabilities increased from Rs 10.54 crore in March 2019 to Rs 10.73 crore in March 2024, while total assets grew from Rs 10.54 crore to Rs 10.73 crore in the same period. The book value per share has improved from Rs 18.95 in March 2019 to Rs 23.22 in March 2024. However, the company reported no profit before tax from March 2020 to March 2023, with a notable cash flow from operating activities consistently at Rs 0.00 during these years. Overall, KMS Medisurgi has shown growth in its equity and asset base while managing to reduce its long-term debt.

Has KMS Medisurgi declared dividend?

No Dividend History Available